Markets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...

Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...

Institutional investors injected over Rs 7,400 crore into Adani Ports and Special Economic Zone (APSEZ) on Monday through significant block...

Emcure Pharmaceuticals saw a significant block deal where BC Investments IV Limited sold 18 lakh shares for Rs 289 crore to Norges Bank. Th...

Bain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...

Investors are becoming selective, focusing on earnings visibility and strong balance sheets. Opportunities are emerging in sectors like IT,...

The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pe...

Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...

Emcure Pharmaceuticals' shares could see action following a Goods and Services Tax search at its Mumbai offices. The inspection concluded t...

Pune-based Emcure Pharmaceuticals reported a 13.4% year-on-year rise in consolidated revenue to ₹2,270 crore in the September quarter, supp...

Markets experienced volatility within a tight range, closing slightly lower, continuing the consolidation trend. TCS is set to release its ...

Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal chall...

Pune-based Emcure Pharmaceuticals listed at Rs 1,325, a 31.4% premium on Rs 1,008 IPO price. QIBs subscribed 195.8 times, non-institutional...

Before listing, the company's shares traded at a Rs 360 premium in the grey market. It raised Rs 582 crore from anchor investors, including...

Emcure Pharma IPO: Emcure Pharmaceuticals IPO, with marquee investors like Goldman Sachs, offers a fresh equity issuance and OFS. Namita Th...

Shark Tank's Namita Thapar, who is part of Emcure Pharmaceuticals' promoter group, is set to earn approximately Rs 127 crore through the up...

Private equity major Blackstone is selling its stake in Pune-based Emcure Pharmaceuticals to Bain Capital.